Full access to Entrepreneur for $5
Subscribe

Here's Why You Should Hold Onto Select Medical (SEM) Now

Select Medical (SEM) is a long-term player on the back of its leadership position in acute care services.

By
This story originally appeared on Zacks

Select Medical Holdings Corp. SEM is poised to grow on the back of its growing patient admissions, diversified business, increasing top line, favorable cash flows, plus acquisitions and partnerships with various healthcare entities.

- Zacks

The company is a leading operator in its business segments, based on the number of facilities in the United States. Its leadership position and reputation as a high-quality, cost-effective healthcare provider in each of its business segments allows it to attract patients and employees, aids in marketing efforts to referral sources and helps negotiate payor contracts. As of Jun 30, 2021, the company had operations in 46 states and the District of Columbia. It operated 99 critical illness recovery hospitals in 28 states, 30 rehabilitation hospitals in 12 states and 1,833 outpatient rehabilitation clinics in 38 states and the District of Columbia. Concentra, a joint venture subsidiary, operated 518 occupational health centers in 41 states as of Jun 30 2021.

With its presence in these areas, the company is well-positioned to benefit from rising demand for medical services owing to an aging population in the United States, which will drive growth across its business segments.

The following factors reflect the company’s strong business enterprise and why holding the stock over the long term will fetch good investment gains.

Increasing Top Line: Revenues have been increasing over the years. The same was up 17.5% in the first six months of 2021. Expansion of facilities and the rising incidence of diseases will steadily increase patient admissions, fuelling growth in turn.

Proven Financial Performance and Solid Cash Flow: The company has an established track record of improving the financial performance of its facilities owing to its disciplined approach to revenue growth, expense management and a firm focus on free cash flow generation. This, in turn, enables it to deploy adequate funds to its business. It0 expects to generate approximately $450-$500 million of free cash flow in the upcoming years.

Sturdy Inorganic Growth: Since its inception in 1997 to date, the company has completed many significant acquisitions including the buyouts of Physiotherapy, Concentra and U.S. HealthWorks. It improved the operating performance of these businesses over time by applying its standard operating practices and realizing efficiencies from its centralized operations and management. These takeovers complemented the company’s organic growth.

Successful Partnerships With Large Healthcare Systems: Over the past several years, the company has teamed up with large healthcare systems to provide post-acute care services. It offers operating expertise to these ventures through its experience in running critical illness recovery hospitals, rehabilitation hospitals and outpatient rehabilitation facilities. Alliances with other healthcare entities also helped the company grow its top line.

Strong Guidance: Following second-quarter 2021 results, the company revised its earnings estimates for the second time this year. Revenues are now estimated to be $5.85-$6.05 billion, up from the previous outlook of $5.7-$5.9 billion (indicating 7.5% growth from the 2020 reported figure). Adjusted EBITDA for 2021 is forecast between $970 million and $1 billion, hinting at growth from the prior guidance of $870-$900 million (suggesting 23% growth from the 2020 reported figure). Earnings per share are expected within $2.91-$3.08, higher than the previous projection of $2.41-$2.58 for the current year (implying 55.2% jump from the 2020 reported figure).

For the 2021-2023 forecast period, the company’s long-term guidance for revenues, adjusted EBITDA and earnings per share were unchanged from the prior outlook. The company is targeting a revenue CAGR in the range of 4-6%, adjusted EBITDA in the 7-8% band and EPS within 17-20%. A strong guidance instills investors’ confidence in the stock.

Bottomline

Select Medical, currently carrying a Zacks Rank #3 (Hold), is strongly placed for growth over the long haul. Year to date, the stock with a market capitalization of $4.83 billion has gained 29% compared with its industry’s growth of 16.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 

Zacks Investment Research

Image Source: Zacks Investment Research

Other stocks in the same space, namely Community Health Systems, Inc. CYH, Tenet Healthcare Corporation THC and Da Vita Inc. DVA, have also rallied 49%, 82% and 4.5%, respectively, over the same time frame.



 



Tech IPOs With Massive Profit Potential

In the past few years, many popular platforms and like Uber and Airbnb finally made their way to the public markets. But the biggest paydays came from lesser-known names.

For example, electric carmaker X Peng shot up +299.4% in just 2 months. Think of it this way…

If you had put $5,000 into XPEV at its IPO in September 2020, you could have cashed out with $19,970 in November.

With record amounts of cash flooding into IPOs and a record-setting stock market, this year’s lineup could be even more lucrative.

See Zacks Hottest Tech IPOs Now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

DaVita Inc. (DVA): Free Stock Analysis Report

 

Tenet Healthcare Corporation (THC): Free Stock Analysis Report

 

Community Health Systems, Inc. (CYH): Free Stock Analysis Report

 

Select Medical Holdings Corporation (SEM): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research